---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Safety questions"
description: "Safety questions on Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: How often does Enhertu cause lung disease (ILD) in HER2-low breast cancer? What are the most common Enhertu side effects in HER2-low or HER2-ultralow breast cancer? How do Enhertu side effects compare with chemotherapy in DESTINY-Breast06? What were the most common Enhertu side effects in DESTINY-Breast04? 8 further questions follow. 12 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Safety questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)

Safety questions that apply to every indication of Enhertu are on [Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Safety](https://www.evicenter.com/medical-information/enhertu/safety).

## Safety

<a id="enhertu-ild-incidence"></a>

### How often does Enhertu cause lung disease (ILD) in HER2-low breast cancer?

> “ILD and pneumonitis, including Grade 5 cases, were reported in DESTINY-Breast06; the majority of events were Grade 1 or 2 (n=43/49)<sup>2,k</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=ILD%20and%20pneumonitis%2C%20including%20Grade,were%20Grade%201%20or%202)

> “Adjudicated as
> drug-induced ILD, n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	All
> Grades	
> ENHERTU
> 5.4 mg/kg (n=434)	7 (1.6)	36 (8.3)	3 (0.7)	0	3 (0.7)	49 (11.3)
> Chemotherapy (n=417)	0	1 (0.2)	0	0	0	1 (0.2)”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Adjudicated%20as,1%20%280.2%29)

> “Of the 434 patients treated with ENHERTU 5.4 mg/kg, ILD occurred in 11.3% of patients (n=49/434)<sup>2</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Of%20the%20434%20patients%20treated,occurred%20in%2011.3%25%20of%20patients)

> “In DESTINY-Breast06, median time to onset of adjudicated drug-induced ILD in patients treated with ENHERTU was 141 days (range: 37 to 835)<sup>2</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=In%20DESTINY%2DBreast06%2C%20median%20time%20to,141%20days%20%28range%3A%2037%20to)

> “Grade 5=fatal cases.<sup>5</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Grade%205%3Dfatal)

> “In DESTINY-Breast04, Grade 5 ILD/pneumonitis events were observed in 0.8% of patients (n=3/371)<sup>1,5,x</sup>”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=In%20DESTINY%2DBreast04%2C%20Grade%205%20ILD%2Fpneumonitis%20events%20were%20observed%20in%200.8%25%20of%20patients)

> “Of the 371 patients treated with ENHERTU 5.4 mg/kg, ILD occurred in 12.1% of patients (n=45/371)<sup>5</sup>”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=Of%20the%20371%20patients%20treated,occurred%20in%2012.1%25%20of%20patients)

> “Metastatic Breast Cancer and Other Solid Tumors (5.4 mg/kg)
>
> In patients treated with ENHERTU 5.4 mg/kg, ILD occurred in 12% of patients. Median time to first onset was 5.5 months (range: 0.9 to 31.5). Fatal outcomes due to ILD and/or pneumonitis occurred in 0.9% of patients treated with ENHERTU.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Metastatic%20Breast%20Cancer%20and%20Other,of%20patients%20treated%20with%20ENHERTU.)

Note: DESTINY-Breast06: HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy, adjudicated drug-induced ILD, ENHERTU n=434 vs chemotherapy n=417 (table columns are Grades 1 to 5 and all grades). DESTINY-Breast04: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients, ENHERTU n=371. The last passage is the pooled safety population of the Prescribing Information (2233 patients with several tumor types treated with 5.4 mg/kg).

<a id="enhertu-neutropenia"></a>

### Does Enhertu cause neutropenia (low neutrophil count)?

> “Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC] <1.0 to 0.5 x 10<sup>9</sup>/L), interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 10<sup>9</sup>/L), interrupt ENHERTU until resolved to Grade 2 or less, then reduce dose by 1 level. For febrile neutropenia (ANC <1.0 x 10<sup>9</sup>/L and temperature >38.3º C or a sustained temperature of ≥38º C for more than 1 hour), interrupt ENHERTU until resolved, then reduce dose by 1 level.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Severe%20neutropenia%2C%20including%20febrile%20neutropenia%2C,resolved%2C%20then%20reduce%20dose%20by%201%20level.)

> “Metastatic Breast Cancer and Other Solid Tumors (5.4 mg/kg)
>
> In patients treated with ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 65% of patients. Nineteen percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 22 days (range: 2 to 939). Febrile neutropenia was reported in 1% of patients.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=by%201%20level.-,Metastatic%20Breast%20Cancer%20and%20Other%20Solid%20Tumors%20%285.4%20mg%2Fkg%29,reported%20in%201%25%20of%20patients.)

> “Selected laboratory abnormalities in patients in DESTINY-Breast06<sup>1</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Selected%20laboratory%20abnormalities%20in%20patients%20in)

> “Decreased neutrophil
> count	75	27	53	20”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Decreased%20neutrophil,20)

> “Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Percentages%20were%20calculated%20using%20patients,post%2Dtreatment%20measurements%20as%20the%20denominator.)

Note: The second passage is the pooled safety population (2233 patients with several tumor types treated with 5.4 mg/kg). The DESTINY-Breast06 row gives all grades and Grades 3-4 for ENHERTU (n=434), then all grades and Grades 3-4 for chemotherapy (n=417), as percentages.

<a id="enhertu-left-ventricular-dysfunction"></a>

### Does Enhertu cause heart problems (left ventricular dysfunction)?

> “Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular dysfunction (LVD) has been observed with anti-HER2 therapies, including ENHERTU. Assess left ventricular ejection fraction (LVEF) prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVD through treatment interruption. When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Patients%20treated%20with%20ENHERTU%20may,prior%20to%20initiation%20of%20treatment.)

> “Metastatic Breast Cancer and Other Solid Tumors (5.4 mg/kg)
>
> In patients treated with ENHERTU 5.4 mg/kg, LVD was reported in 4.6% of patients, of which 0.6% were Grade 3 or 4.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=initiation%20of%20treatment.-,Metastatic%20Breast%20Cancer%20and%20Other%20Solid%20Tumors%20%285.4%20mg%2Fkg%29,were%20Grade%203%20or%204.)

Note: The incidence figure is from the pooled safety population (2233 patients with several tumor types treated with 5.4 mg/kg).

<a id="enhertu-thrombocytopenia"></a>

### Does Enhertu lower platelet counts (thrombocytopenia)?

> “Thrombocytopenia
>
> For Grade 3 thrombocytopenia (platelets <50 to 25 x 10<sup>9</sup>/L) interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose. For Grade 4 thrombocytopenia (platelets <25 x 10<sup>9</sup>/L) interrupt ENHERTU until resolved to Grade 1 or less, then reduce dose by 1 level.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Thrombocytopenia,reduce%20dose%20by%201%20level.)

> “Selected laboratory abnormalities in patients in DESTINY-Breast06<sup>1</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Selected%20laboratory%20abnormalities%20in%20patients%20in)

> “Decreased platelet
> count	48	6	25	1”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Decreased%20platelet,1)

> “Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Percentages%20were%20calculated%20using%20patients,post%2Dtreatment%20measurements%20as%20the%20denominator.)

Note: The DESTINY-Breast06 row gives all grades and Grades 3-4 for ENHERTU (n=434), then all grades and Grades 3-4 for chemotherapy (n=417), as percentages.

## Side effects

<a id="enhertu-common-side-effects-db06"></a>

### What are the most common Enhertu side effects in HER2-low or HER2-ultralow breast cancer?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “The safety of ENHERTU was evaluated in 434 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast06. The median duration of treatment was 11 months (range: 0.4 to 39.6) for patients who received ENHERTU.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=The%20safety%20of%20ENHERTU%20was,for%20patients%20who%20received%20ENHERTU.)

> “The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased white blood cell count (86%), decreased neutrophil count (75%), nausea (70%), decreased hemoglobin (69%), decreased lymphocyte count (66%), fatigue (53%), decreased platelet count (48%), alopecia (48%), increased alanine aminotransferase (44%), increased blood alkaline phosphatase (43%), increased aspartate aminotransferase (41%), decreased blood potassium (35%), diarrhea (34%), vomiting (34%), constipation (32%), decreased appetite (26%), COVID-19 (26%), and musculoskeletal pain (24%).”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=decreased%20neutrophil%20count.-,The%20most%20common%20%28%E2%89%A520%25%29%20adverse%20reactions%2C%20including%20laboratory%20abnormalities%2C%20were,%2826%25%29%2C%20and%20musculoskeletal%20pain%20%2824%25%29.)

Note: Rates are from the DESTINY-Breast06 safety population (ENHERTU n=434; HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy).

<a id="enhertu-side-effects-vs-chemotherapy"></a>

### How do Enhertu side effects compare with chemotherapy in DESTINY-Breast06?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “Common adverse reactions (≥10% All Grades or ≥2% Grades 3 or 4) in DESTINY-Breast06<sup>1</sup>
> Adverse
> reactions	ENHERTU 5.4 mg/kg
> (n=434)	Chemotherapy
> (n=417)
> All Grades
> (%)	Grades 3-4 (%)	All Grades
> (%)	Grades 3-4
> (%)
> Gastrointestinal
> disorders	Nausea	70	2.1	30	0.5
> Diarrhea	34	2.3	27	2.6
> Vomiting	34	1.4	12	0.2
> Constipation	32	0.7	15	0.5
> Abdominal pain<sup>a</sup>	20	0.5	14	0.2
> Stomatitis<sup>b</sup>	15	0	11	0.5
> Dyspepsia	12	0	4.8	0
> General disorders
> and administration
> site conditions	Fatigue<sup>c</sup>	53	4.4	40	2.4
> Pyrexia	12	0.2	7	0
> Skin and
> subcutaneous tissue
> disorders	Alopecia	48	0	21	0.5
> Rash<sup>d</sup>	12	0.2	43	8
> Metabolism and
> nutrition disorders	Decreased appetite	26	1.4	12	0.5
> Infections and infestations	COVID-19<sup>e</sup>	26	0.9	13	1
> Upper respiratory tract infection<sup>f</sup>	19	0	9	0
> Musculoskeletal and
> connective tissue
> disorders	Musculoskeletal pain<sup>g</sup>	24	0.5	23	1.9
> Nervous system disorders	Headache<sup>h</sup>	18	0.5	10	0
> Dysgeusia	12	0.2	6	0
> Respiratory,
> thoracic, and
> mediastinal
> disorders	Cough	16	0	9	0
> Interstitial lung disease<sup>i</sup>	11	0.7	0.2	0
> Epistaxis	10	0	3.6	0.2”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Common%20adverse%20reactions%20%28%E2%89%A510%25%20All,0.2)

> “Events were graded using NCI-CTCAE v.5.0.”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Events%20were%20graded%20using%20NCI%2DCTCAE%20v.5.0.)

> “The median duration of treatment was 11 months (range: 0.4-39.6) with ENHERTU and 5.6 months (range: 0.1-35.9) with chemotherapy<sup>1,2</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=The%20median%20duration%20of%20treatment,5.6%20months%20%28range%3A%200.1%2D35.9%29%20with)

Note: Columns, in order: ENHERTU 5.4 mg/kg (n=434) all grades and Grades 3-4, then chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417) all grades and Grades 3-4, as percentages. Several terms group related events, as defined in the footnotes on the source page.

<a id="enhertu-common-side-effects-db04"></a>

### What were the most common Enhertu side effects in DESTINY-Breast04?

Applies to: Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

> “The safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in DESTINY-Breast04. The median duration of treatment was 8 months (range: 0.2 to 33) for patients who received ENHERTU.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=The%20safety%20of%20ENHERTU%20was%20evaluated%20in%20371,for%20patients%20who%20received%20ENHERTU.)

> “The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (70%), decreased hemoglobin (64%), decreased neutrophil count (64%), decreased lymphocyte count (55%), fatigue (54%), decreased platelet count (44%), alopecia (40%), vomiting (40%), increased aspartate aminotransferase (38%), increased alanine aminotransferase (36%), constipation (34%), increased blood alkaline phosphatase (34%), decreased appetite (32%), musculoskeletal pain (32%), diarrhea (27%), and decreased blood potassium (25%).”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=thrombocytopenia%2C%20and%20neutropenia.-,The%20most%20common%20%28%E2%89%A520%25%29%20adverse%20reactions%2C%20including%20laboratory%20abnormalities%2C%20were,and%20decreased%20blood%20potassium%20%2825%25%29.)

Note: Rates are from the DESTINY-Breast04 safety population (ENHERTU n=371; HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients).

<a id="enhertu-serious-side-effects-db06"></a>

### How often were Enhertu side effects serious or fatal in DESTINY-Breast06?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, COVID-19, febrile neutropenia, and hypokalemia. Fatalities due to adverse reactions occurred in 2.8% of patients including ILD (0.7%); sepsis (0.5%); and COVID-19 pneumonia, bacterial meningoencephalitis, neutropenic sepsis, peritonitis, cerebrovascular accident, general physical health deterioration (0.2% each).”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Serious%20adverse%20reactions%20occurred%20in,physical%20health%20deterioration%20%280.2%25%20each%29.)

> “Clinically
> relevant AR
> considerations	ENHERTU
> 5.4 mg/kg (n=434)	Chemo- therapy
> (n=417)”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Clinically,%28n%3D417%29)

> “Serious adverse reactions<sup>2</sup>	20%	16%”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Serious%20adverse,16%25)

Note: DESTINY-Breast06. In the table rows, the first percentage is ENHERTU (n=434) and the second is chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417).

<a id="enhertu-discontinuation-db06"></a>

### How often did patients stop or reduce Enhertu because of side effects (DESTINY-Breast06)?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “ENHERTU was permanently discontinued in 14% of patients. The most frequent adverse reaction (>2%) associated with permanent discontinuation was ILD/pneumonitis. Dose interruptions due to adverse reactions occurred in 48% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were COVID-19, decreased neutrophil count, anemia, pyrexia, pneumonia, decreased white blood cell count, and ILD. Dose reductions occurred in 25% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were nausea, fatigue, decreased platelet count, and decreased neutrophil count.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=ENHERTU%20was%20permanently%20discontinued%20in,count%2C%20and%20decreased%20neutrophil%20count.)

> “Clinically
> relevant AR
> considerations	ENHERTU
> 5.4 mg/kg (n=434)	Chemo- therapy
> (n=417)”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Clinically,%28n%3D417%29)

> “Discontinuations due to adverse reactions<sup>2</sup>	14%	9%”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Discontinuations%20due%20to%20adverse,9%25)

> “Dose interruptions due to adverse reactions<sup>6</sup>	48%	38%”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Dose%20interruptions%20due%20to%20adverse,38%25)

> “Dose reductions due to adverse reactions<sup>2</sup>	25%	39%”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Dose%20reductions%20due%20to%20adverse,39%25)

Note: DESTINY-Breast06. In the table rows, the first percentage is ENHERTU (n=434) and the second is chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417).

<a id="enhertu-serious-side-effects-db04"></a>

### How often were Enhertu side effects serious or fatal in DESTINY-Breast04?

Applies to: Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

> “Serious adverse reactions occurred in 28% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, pneumonia, dyspnea, musculoskeletal pain, sepsis, anemia, febrile neutropenia, hypercalcemia, nausea, pyrexia, and vomiting. Fatalities due to adverse reactions occurred in 4% of patients including ILD/pneumonitis (3 patients); sepsis (2 patients); and ischemic colitis, disseminated intravascular coagulation, dyspnea, febrile neutropenia, general physical health deterioration, pleural effusion, and respiratory failure (1 patient each).”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=Serious%20adverse%20reactions%20occurred%20in%2028%25,respiratory%20failure%20%281%20patient%20each%29.)

> “Clinically
> relevant AR
> considerations	ENHERTU
> 5.4 mg/kg
> (n=371)	Chemo- therapy
> (n=172)”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=Clinically,%28n%3D172%29)

> “Serious adverse reactions<sup>1,5,6</sup>	28%	25%”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=Serious%20adverse,25%25)

Note: DESTINY-Breast04 safety population: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients. In the table rows, the first percentage is ENHERTU (n=371) and the second is physician's choice chemotherapy (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel; n=172).

<a id="enhertu-discontinuation-db04"></a>

### How often did patients stop or reduce Enhertu because of side effects (DESTINY-Breast04)?

Applies to: Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

> “ENHERTU was permanently discontinued in 16% of patients, of which ILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 39% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, fatigue, anemia, leukopenia, COVID-19, ILD/pneumonitis, increased transaminases, and hyperbilirubinemia. Dose reductions occurred in 23% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, thrombocytopenia, and neutropenia.”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=ENHERTU%20was%20permanently%20discontinued%20in%2016%25,fatigue%2C%20nausea%2C%20thrombocytopenia%2C%20and%20neutropenia.)

> “Clinically
> relevant AR
> considerations	ENHERTU
> 5.4 mg/kg
> (n=371)	Chemo- therapy
> (n=172)”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=Clinically,%28n%3D172%29)

> “Discontinuations due to adverse reactions<sup>1,5</sup>	16%	8%”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=Discontinuations%20due%20to%20adverse,8%25)

> “Dose interruptions due to adverse reactions<sup>1,4,6</sup>	39%	42%”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=Dose%20interruptions%20due%20to%20adverse,42%25)

> “Dose reductions due to adverse reactions<sup>1,5,6</sup>	23%	38%”

Source: [ENHERTU: Additional Data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/destiny-breast-04#:~:text=Dose%20reductions%20due%20to%20adverse,38%25)

Note: DESTINY-Breast04 safety population: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients. In the table rows, the first percentage is ENHERTU (n=371) and the second is physician's choice chemotherapy (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel; n=172).

<a id="enhertu-hair-loss"></a>

### Does Enhertu cause hair loss?

Applies to: Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

> “Common adverse reactions (≥10% All Grades or ≥2% Grades 3 or 4) in DESTINY-Breast06<sup>1</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Common%20adverse%20reactions%20%28%E2%89%A510%25%20All,Grades%203%20or%204%29%20in)

> “Alopecia	48	0	21	0.5”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Alopecia,0.5)

> “Incidence of select common adverse reactions<sup>4</sup>”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=Incidence%20of%20select%20common%20adverse)

> “Alopecia	32.5	15.9	0	0”

Source: [ENHERTU: Safety data, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/safety#:~:text=0-,Alopecia,0)

> “Per NCI-CTCAE v.5.0, the highest NCI-CTCAE grade for alopecia is Grade 2.<sup>3</sup>”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=Per%20NCI%2DCTCAE%20v.5.0%2C%20the%20highest%20NCI%2DCTCAE%20grade%20for%20alopecia%20is%20Grade)

Note: DESTINY-Breast06. First row: ENHERTU (n=434) all grades and Grades 3-4, then chemotherapy (n=417) all grades and Grades 3-4, as percentages. Second row: ENHERTU Grades 1, 2, 3, and 4, as percentages.

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/clinical-trials)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/guidelines)
